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A B S T R A C T
Information on sales and emission of selected pharmaceuticals were used to predict their concentrations in
Japanese wastewater influent through a> 300 of pharmaceuticals data sink. A combined wastewater-based
epidemiology and environmental risk analysis follow was established. By comparing predicted environmental
concentrations (PECs) of pharmaceuticals in wastewater influent against measured environmental concentra-
tions (MECs) reported in previous studies, it was found that the model gave accurate results for 17 pharma-
ceuticals (0.5 < PEC/MEC < 2), and acceptable results for 32 out of 40 pharmaceuticals (0.1 < PEC/
MEC < 10). Although the majority of pharmaceuticals considered in the model were antibiotics and analgesics,
pranlukast, a receptor antagonist, was predicted to have the highest concentration in wastewater influent. With
regard to the composition of wastewater effluent, the Estimation Program Interface (EPI) suite was used to
predict pharmaceutical removal through activated sludge treatment. Although the performance of the EPI suite
was variable in terms of accurate prediction of the removal of different pharmaceuticals, it could be an efficient
tool in practice for predicting removal under extreme scenarios. By using the EPI suite with input data on PEC in
the wastewater influent, the PEC values of pharmaceuticals in wastewater effluent were predicted. The con-
centrations of 26 pharmaceuticals were relatively high (> 1 μg/L), and the PECs of 6 pharmaceuticals were
extremely high (> 10 μg/L) in wastewater effluent, which could be attributed to their high usage rates by
consumers and poor removal rates in wastewater treatment plants (WWTPs). Furthermore, environmental risk
assessment (ERA) was carried out by calculating the ratio of predicted no effect concentration (PNEC) to PEC of
different pharmaceuticals, and it was found that 9 pharmaceuticals were likely to have high toxicity, and 54
pharmaceuticals were likely to have potential toxicity. It is recommended that this is further investigated in
detail. The priority screening and environmental risk assessment results on pharmaceuticals can provide reliable
basis for policy-making and environmental management.
1. Introduction
Pharmaceuticals are contaminants of emerging concern due to their
potential threat to the aquatic ecosystem and human health (Boxall
et al., 2012; Ebele et al., 2017; Schwarzenbach et al., 2006). Pharma-
ceuticals comprise a large, diverse group of compounds, including an-
tibiotics, hormones, anti-inflammatory drugs, antiepileptic drugs, blood
lipid regulators, β-blockers, contrast media, and cytostatic drugs
(Mehrabad et al., 2016). Effluent from wastewater treatment plants
(WWTPs) is the main source of pharmaceuticals released into the en-
vironment (Daughton and Ternes 1999), and reported pharmaceutical
concentrations in wastewater treatment systems range from ng/L to μg/
L (Verlicchi et al., 2012). Due to their limited removal efficiency by
conventional wastewater treatment processes, a large number of re-
sidual pharmaceuticals are discharged from WWTPs, and contaminate
receiving water bodies. According to previous studies, diclofenac was
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widely detected in aquatic environments around the world, and it was
indicated to have high environmental risk in aquatic environments as
well as ethinylestradiol and atorvastatin (Singh et al., 2019; Zhou et al.,
2019). Besides, given that many drinking water treatment plants
(DWTPs) use source water impacted by wastewater, a possible health
risk may exist in drinking water contaminated with pharmaceuticals
and personal care products (PPCPs) (Benotti et al., 2008). Traces of
pharmaceutical pollution have been found in Canada, Germany, Italy,
UK, and the USA (Jones et al., 2005; Zwiener, 2007). Therefore, mon-
itoring pharmaceuticals in wastewater is of vital importance in identi-
fying (and hence addressing) both environmental risk and human risk.
Highly sensitive analytical techniques, such as liquid chromato-
graphy-tandem mass spectrometry (LC-MS/MS), are used to monitor
pharmaceutical concentrations in wastewater. Determination of all
pharmaceuticals in a wastewater sample is necessary to estimate ac-
curately the overall risk due to their presence. However, this involves
complex pretreatment, expensive operating costs, and lengthy analysis
(Petrović et al., 2005), which suggests that a method based on selected,
priority pharmaceuticals in wastewater would be beneficial to screen
the priority of pharmaceuticals considering the environmental risk.
Moreover, Ottmar et al. found that cited scientific research had not
considered prescription frequency or daily load, indicating a gap in
understanding of the actual situation of pharmaceutical pollution
(Ottmar et al., 2010). Thus, a comprehensive strategy for evaluation of
priority pharmaceuticals in wastewater is necessary to restrict mon-
itoring to a limited number of the most hazardous drugs. Several studies
have estimated the predicted environmental concentration (PEC) of
pharmaceuticals in receiving water in order to determine their priority
order. For example, the average consumption of paracetamol and
metformin, the most commonly prescribed pharmaceuticals in the UK,
was used to predict their environmental concentrations of 11.96 and
6.30 μg/L, respectively (Jones et al., 2002). In China, 13 pharmaceu-
ticals were classified as priority pharmaceuticals based on available
consumption data (Li et al., 2019). Gómez-Canela et al. prioritized the
occurrence of pharmaceuticals in rivers in Catalonia according to
pharmaceutical consumption data (Gómez-Canela et al., 2019).
In calculating the PEC of pharmaceuticals in receiving water, three
relevant factors should be considered: pharmaceutical consumption,
excretion rate, and the removal efficiency of WWTPs. Pharmaceutical
consumption is calculated from data on the sales of pharmaceuticals,
obtained from medical authorities. In practice, when pharmaceuticals
are excreted after metabolism, a variety of metabolites enter the was-
tewater sewage system together with their parent compounds in urine
and feces. Hence, it is necessary to consider the excretion efficiencies by
which PECs become refined, i.e., the percentage of the drug excreted
with respect to its parent compound. To date, the PEC of pharmaceu-
ticals in effluent has been investigated using factors related to con-
sumption and measured removal efficiencies in target WWTPs (Alder
et al., 2010). The occurrence of pharmaceuticals in surface waters has
also been evaluated, with the results showing that concentrations of
pharmaceuticals correlated well with consumption data (Scheurer
et al., 2009; ter Laak et al., 2010). The findings indicate that, among
other criteria, international or national sales data can be a valuable
resource from which to select relevant pharmaceuticals for monitoring
and hence to estimate loads and average environmental concentrations
in wastewater. In Japan, the occurrence of pharmaceuticals in the
wastewater system has been evaluated in previous studies, in particular
during the period from 2007 to 2009, when analgesics (i.e., acet-
aminophen) and antibiotics (i.e., ampicillin) were detected at high
concentrations (Kim et al., 2009; Kobayashi et al., 2006; Nakada et al.,
2007; Narumiya et al., 2009). Two prediction studies of pharmaceu-
ticals in wastewater have been performed in Japan (Azuma et al., 2015;
Suzuki, 2012), with estimated concentrations of 15 and 7 pharmaceu-
ticals respectively; in both cases, the number of target pharmaceuticals
was limited. Obviously, more pharmaceuticals should be selected to
enhance accurate prediction in Japan.
Previous studies mainly focused on the well-investigated pharma-
ceuticals, while the priority of some important but high environmental
risk pharmaceuticals could be ignored, and these compounds were
carefully investigated in this study. Moreover, a huge data source in-
cluding>300 pharmaceuticals with different varieties in pharmaco-
logic classification were applied, and a great many information of these
pharmaceuticals were provided for calculation. Furthermore, a novel
analysis work flow integrating wastewater-based epidemiology and
environmental risk was established, which was from sale data of
pharmaceuticals, to their environmental risks, and then to screening the
priority of pharmaceuticals. The overall aim of this study is to develop a
predictive approach to estimate pharmaceutical concentrations in the
Japanese wastewater system by using pharmaceutical industrial sales
data and to apply this approach to assess the environmental risk of
pharmaceutical contamination. First, an updated list of priority phar-
maceuticals was obtained in terms of sales volume, and their PECs in
wastewater influent were estimated with respect to excretion rate from
the human body and compared against measured environmental con-
centrations (MECs). Second, after evaluating the feasibility of removal
by comparing reported and predicted removal efficiencies of pharma-
ceuticals in WWTPs, the predicted concentrations of PPCPs in waste-
water effluent were estimated. Finally, the environmental risks posed
by different pharmaceuticals were evaluated from their PECs in was-
tewater systems, and priority pharmaceuticals proposed in terms of
environmental risk.
2. Methods
2.1. Pharmaceutical discharge loads
Discharge loads of pharmaceuticals in wastewater were calculated
from sales data on pharmaceuticals in Japan, based on the sale yield of
pharmaceuticals rather than usage by patients. Sales volumes of over-
the-counter drug (OTC) pharmaceuticals in terms of numbers of packs
sold per year were obtained from statistics compiled by Japanese
Ministry of Health, Labour and Welfare in 2014, which was public from
2017 (Ministry of Health, Labour and Welfare, 2018). Although the
local sale data could improve the prediction performance locally, the
national sale data can provide the priority pharmaceuticals from the
perspective of national policymaking. In addition, the yearly change of
pharmaceutical consumption and the consumption behavior of phar-
maceuticals in Japanese local area were shown in Figs. S1 and S2, in-
dicating that Japan has relatively stable pharmaceutical consumption in
time and space. Furthermore, the concentration of pharmaceutical in
wastewater influent was strongly related to the water consumption. The
average water consumption in Japan was approximately 300 L per
capita, per day with the range of 267 (lowest)–338 (highest) L per ca-
pita, per day, which indicated the water consumption fluctuated around
10%. Thus, the national sale data were applied in this study.
2.2. PECs of pharmaceuticals in wastewater influent
Following European Medicines Agency (EMA) guidelines (Huschek
et al., 2004), PECs in wastewater influent (PECinf, EMA) were estimated
from per capita annual consumption in Japan using the following for-
mula:
=
× ×
PEC A
P V365inf, EMA (1)
where A is the annual sale amount of pharmaceuticals in Japan (kg per
year), P is the population in the area, and V is the volume of wastewater
per capita, per day (0.3 m3) (Ministry of Economy Trade and Industry,
Japan, 2010; Ogawa 2006). The population (P) in Japan was set as
125,583,658, according to the Japanese government report (Statistics
Bureau of Japan, 2017). However, this formula does not consider the
influence of the excretion rate. To improve the predictions, the effect of
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excretion efficiencies (f) of pharmaceuticals from humans was in-
corporated in the calculation of PEC in the influent (PECinf), indicating
the actual amount of active substances entering the sewage system:
=
× ×
×PEC A
P V
f
365inf (2)
Data on renal excretion efficiencies of humans were obtained from
the Pharmaceuticals and Medical Devices Agency, Japan
(Pharmaceuticals and Medical Devices Agency, 2019), the Japan
Pharmaceutical Information Center (Japan Pharmaceutical Information
Center, 2004), the KEGG (Kyoto Encyclopedia of Genes and Genomes)
database (Kanehisa et al., 2016), Drugbank (Wishart et al., 2017), and
previous studies (National Information Program on Antibiotics, 2016;
Down et al., 1974; Furuta et al., 2002; Green et al., 2015; Gregory et al.,
1993; Naito and Yoshikawa 2010; Rhee et al., 2013; Sakashita et al.,
1993; Spratto and Woods 2010; Teramoto et al., 2013; Wang et al.,
2012). The details of excretion efficiencies were presented in
Supplementary material. Given the variation in the reported values of
excretion efficiency, we selected the highest value to account for the
most extreme case. For those pharmaceuticals where excretion effi-
ciencies could not be found in databases or the open literature, we set
the excretion efficiency to 100% for the most extreme case. In Japan,
the average retention time of wastewater in sewage system is generally
less than 6 h (Kanagawa Sewerage Work Foundation, 2019), indicating
that the pharmaceuticals and their metabolites can be degraded in the
WWTPs with relatively short time, so the transformation of pharma-
ceuticals can be expected in WWTPs.
To clearly illustrate the calculation of PECinf, the example of sul-
piride was provided as follows: Firstly, the sale of sulpiride was cal-
culated by the sale data of commercially available tablets and capsules
including 26,795,000 tablets of 100 mg, 373,075,000 tablets of 50 mg
and 28,795,000 capsules of 50 mg (Ministry of Health, Labour and
Welfare, 2018), indicating that the total yearly amount of sulpiride in
Japan was 22,773 kg; Secondly, the excretion efficiencies of sulpiride
was 70%, indicating the excreted amount of sulpiride was 15,941 kg;
Thirdly, the concentration was calculated by excreted amount, water
consumption, and population as shown in Equation (2), so the PECinf of
sulpiride was calculated to be 1159.23 ng/L.
In evaluating model performance, the ratio of PEC to MEC was used
to establish whether the prediction underestimated or overestimated
the concentration of each pharmaceutical (Verlicchi et al., 2014). The
values of MECs in wastewater influent were obtained from previous
studies (Azuma et al., 2015, 2016; Kobayashi et al., 2006; Nakada et al.,
2007; Narumiya et al., 2009; Suzuki, 2012), and the average con-
centration of the individual pharmaceutical in several previous studies
was used as MEC value in this study. An important influence factor is
the difference between reported and actual consumption (Oosterhuis
et al., 2013), which could be enhanced by the incomplete use of sold
pharmaceuticals and pharmaceuticals obtained from other sources
(Ruhoy and Daughton, 2008). In addition, the temporal consumption
behavior of pharmaceuticals also influences model predictions (You
et al., 2015). Researchers have therefore employed certain criteria re-
lated to PEC/MEC to evaluate the prediction results. For example,
Morasch et al. and Tauxe-Wuersch et al. adopted the following criteria
to classify PEC: 0.1 < PEC/MEC < 10, acceptable (Morasch et al.,
2010; Tauxe-Wuersch et al., 2005); PEC/MEC < 0.1, unacceptably
low; PEC/MEC > 10, unacceptably high. Stricter criteria were pro-
posed by Ort et al.: 0.5 < PEC/MEC < 2, acceptable, PEC/MEC <
0.5, unacceptably low; and PEC/MEC > 2, unacceptably high (Ort
et al., 2009). Table 1 lists the criteria used in the present study in order
to classify PEC.
2.3. PECs of pharmaceuticals in wastewater effluent
Pharmaceutical concentrations in wastewater influent indicate
consumption habits in the study area, and the environmental risk posed
by pharmaceuticals in receiving water relates to their concentrations in
wastewater effluent, which are in turn strongly correlated to the re-
moval performance of WWTPs. In practice, activated sludge is the most
prevalent treatment technology in WWTPs in Japan (Japan Sewage
Works Association, 2016), and so was taken to be the target process in
the present study. First, concentrations of pharmaceuticals in the in-
fluent and the effluent of Japanese WWTPs that use the activated sludge
process based on previous studies were collated (Azuma et al., 2015;
Kobayashi et al., 2006; Nakada et al., 2007; Narumiya et al., 2009;
Suzuki, 2012), and the measured removal efficiencies were then cal-
culated. Predicted removal efficiencies of pharmaceuticals in activated
sludge were computed using the STP script program in the US EPA’s
Estimation Program Interface (EPI) Suite that is widely used to predict
physicochemical properties and removal efficiencies of target con-
taminants in WWTPs (Lu et al., 2019; Lu et al., 2017). This STP script
program provided the removal prediction in WWTPs based on the ty-
pical activated sludge conditions. Although parameters in this script
program can be set for prediction, such as half-lives in the primary
clarifier, aeration vessel and setting tank, the output of BIOWIN script
in EPI suite and EPA draft method was used in this study. Model per-
formance was evaluated by comparing predicted and reported removal
efficiencies. In the STP script, the BIOWIN output and the EPA draft
method for assigning half-lives were used to predict biodegradation and
sorption in activated sludge. In order to evaluate the performance of
predicted removal efficiencies by EPI Suite, the criteria of removal ef-
ficiencies was referred to Table 1.
The PEC of each pharmaceutical in the wastewater effluent was
calculated from:
= ×PEC PEC Reff inf (3)
where R is the removal efficiency predicted by the EPI suite.
2.4. Environmental risk assessment
Pharmaceutical toxicity data were collected from simulated values
obtained using ECOSAR developed by US EPA (Sanderson and
Thomsen, 2007), and the KAshinhou Tool for Ecotoxicity (KATE), an
ecotoxicity prediction system based on quantitative structure-activity
relationship (QSAR) models with log P (Furuhama et al., 2011;
Melnikov et al., 2016), developed by the Center for Health and En-
vironmental Risk Research (CHERR) of the National Institute for En-
vironmental Studies (NIES), Japan. No-observed effect concentration
(NOEC) and effective concentration (EC) (possessing a given percentage
effect, generally 50% effect or EC50) values were compared and the
lowest value divided by an appropriate assessment factor (10) to give
the predicted no-effect concentration (PNEC) (Caldwell et al., 2019).
Referring to previous studies (Ma et al., 2016; Zeng et al., 2018), the
toxicity was divided into 4 levels with respect to the ratio Rt = MEC/
PNEC as follows: high risk (Rt > 1), medium risk (0.1 < Rt < 1), low
risk (0.01 < Rt < 0.1), and no risk (Rt < 0.01).
3. Results and discussion
3.1. Evaluation of PECs with MECs in wastewater influent
Table S1 in Supplementary material lists the measured and
Table 1
Criteria used to classify PEC.
PEC evaluation PEC/MEC ratio
Unacceptably high PEC/MEC > 10
Acceptably high 2 < PEC/MEC < 10
Accurate 0.5 < PEC/MEC < 2
Acceptably low 0.1 < PEC/MEC < 0.5
Unacceptably low PEC/MEC < 0.1
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predicted environmental concentrations of pharmaceuticals in waste-
water influent. Fig. 1 is a scatter plot comparing the predicted and
measured environmental concentrations of the selected compounds
from which it can be readily seen that the predictions of most of the
pharmaceutical PECs are acceptable. The correlation coefficient of the
logarithmic relationship between the PEC and MEC values is 0.52, in-
dicating the feasibility of the concentration prediction method based on
pharmaceutical consumption. Based on the evaluation criteria listed in
Table 1, we found that 32 out of 40 (80.0%) reported pharmaceutical
PECs were acceptable, and 17 out of 40 (42.5%) pharmaceuticals had
accurate PECs, including aspirin (0.86) and disopyramide (1.18). Si-
milar trends were observed in the work by Coetsier et al. who reported
that predicted data were acceptable in 36% of cases considered (11
pharmaceuticals) (Coetsier et al., 2009). Metcalfe et al. compared the
PEC and MEC of four β-blockers, and found that they had obtained
acceptable data at 44% of their sampling points (Metcalfe et al., 2008).
The high level of acceptable predictions made by the present study may
be attributed to high sewage coverage (78.8%, the ratio of population
served by the sewage system to the total population, expressed as a
percentage) (Japan Sewage Works Association, 2019) and the high
usage of separate sewage systems in Japan. Differences between PECs
and MECs could be attributed to the discharge of pharmaceuticals in the
wastewater system and consumption from illegal sources (i.e. clandes-
tine manufacturing of pharmaceuticals). Thus, by basing the prediction
method on pharmaceutical sales rather than consumption, factors such
as unexpected data (i.e. pharmaceuticals distributed without prescrip-
tion or via hospitals) were avoided (Winker et al., 2008). It should be
noted however that Ort et al. observed that national consumption fig-
ures do not take into account drugs dispensed to public hospital in-
patients departments (Ort et al., 2010); this source of inaccuracy could
affect the present study. In addition, transformation of pharmaceuticals
by the retention in sewage and temporal variations in pharmaceutical
consumption would contribute to the discrepancies between sales and
influent concentrations (ter Laak et al., 2010; Oosterhuis et al., 2013).
Moreover, national sales data could be inaccurate if local consumption
patterns differ from those reported in the national sales data. Hence, we
recommend the use of regional consumption data instead of national
data if different consumption patterns are expected. Even though the
collection and analysis of regional data are potentially difficult tasks,
big data technology could facilitate the future direction of such phar-
maceutical retrospective approaches. Overall, based on the results in
Table S1 and Fig. 1, the foregoing work has resulted in an acceptable
tool for the prediction of pharmaceutical concentrations based on sale
information, which will be used for the PEC calculation in the following
section.
3.1.1. Analgesics/anti-inflammatories
Of the reported pharmaceuticals in Japan, analgesics/anti-in-
flammatories (i.e., acetaminophen, salicylic acid, and salicylamide) are
abundant in wastewater influent (> 100 ng/L) (Azuma et al., 2019a,b;
Hanamoto et al., 2018; Narumiya et al., 2009). Other studies on the
occurrence of pharmaceuticals in wastewater influent (i.e., United
States and China) have reported similar findings (Kostich et al., 2014;
Liu and Wong, 2013). Azuma et al. detected loxoprofen, a nonsteroidal
anti-inflammatory drug (NSAID), at high concentration of 5.663 μg/L in
wastewater influent (Azuma et al., 2016); this value was similar to the
PEC of 5.313 μg/L, with PEC/MEC of 0.94. Among analgesics, besides
loxoprofen, the PECs of aspirin and disopyramide were also found to be
accurately predicted with PEC/MEC of 0.86 and 1.18, respectively. The
PEC values for ibuprofen, naproxen, and ketoprofen were acceptably
low (0.1 < PEC/MEC < 0.5). Acetaminophen is a traditional an-
algesic/anti-inflammatory commonly used worldwide, and widely de-
tected at relatively high concentrations in wastewater influent (Burns
et al., 2018; Du et al., 2014). However, acetaminophen exhibited a
significant difference between its PEC (593 ng/L) and its MEC
(9594 ng/L). Similarly, mefenamic acid showed considerable difference
in its PEC and MEC values, with PEC/MEC = 0.03. The PECs of acet-
aminophen and mefenamic acid were unacceptably low. Overall, al-
though the PECs of most analgesics/anti-inflammatories were accep-
table, their PEC values were lower than their MEC values in the
wastewater influent. For analgesics/anti-inflammatories, which are
traditional household pharmaceuticals, their improper disposal (i.e., by
flushing them down into the sewage system or discarding them with
household waste) increased MEC in wastewater influent and disrupted
the model prediction accuracy (Mankes and Silver, 2013). In this case,
the analgesics/anti-inflammatories bypassed human metabolism, con-
tributing to the high MEC of analgesics/inflammatories in wastewater
influent.
3.1.2. Antibiotics
Antibiotics are another abundant group of pharmaceuticals found in
wastewater influent (Guerra et al., 2014). For example, clarithromycin
and levofloxacin have been detected at high concentrations (> 400 ng/
L) (Hanamoto et al., 2018; Narumiya et al., 2009). For macrolide an-
tibiotics, such as clarithromycin, roxithromycin, and azithromycin,
their predicted influent concentrations are close to the measured values
(with PEC/MEC ranging from 0.66 to 2.09), confirming that both the
consumption pattern and excretion factor are properly modeled. In
addition to macrolide antibiotics, PECs of sulfamethoxazole, thiam-
phenicol, and trimethoprim were found to be accurate, with PEC/MEC
ratios of 1.51, 1.54, and 1.40, respectively. Furthermore, the PEC/MEC
ratio of ampicillin was 9.47, indicating an acceptably high PEC in
wastewater influent. Ampicillin is a common β-lactam antibiotic used
to prevent and treat bacterial infections; the hydrolysis of β-lactam
antibiotics has been reported in wastewater (Mitchell et al., 2014).
Once ampicillin is excreted into the sewage system, its effective hy-
drolysis could contribute to its elimination, thus affecting the accuracy
of the PEC. For ofloxacin (excretion rate of 64%) (Dave and Morris,
2016), the PEC value in wastewater influent was far lower than the
measured concentration (PEC/MEC < 0.1), indicating that some other
sources of contamination had not been considered in the prediction
method. For example, improper disposal or unregistered sources (ve-
terinary medicine), as mentioned previously, could contribute to an
increased MEC in wastewater influent.
3.1.3. Receptor antagonists/blockers
In addition to analgesics/anti-inflammatories and antibiotics, an-
tagonists are another important group of pharmaceuticals. In the pre-
sent study, diphenhydramine, sulpiride, atenolol, and pirenzepine were
detected at concentrations of 1530.0, 1234.3, 364.3, and 40.5 ng/L,
with corresponding PEC/MEC ratios of 0.10, 0.94, 1.17, and 0.75, in-
dicating their PECs in wastewater were acceptable. The results are
Fig. 1. Comparison between predicted PECinf and measured MECinf in waste-
water influent.
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consistent with those reported by Metcalfe et al. (Metcalfe et al., 2008).
The stability of these pharmaceuticals in sewer systems is likely to have
contributed to their acceptable prediction (Phung et al., 2017).
3.1.4. Others
For other reported pharmaceuticals, the PEC values of amantadine
(anti-Parkinson), carbamazepine (anticonvulsant), dipyridamole (an-
tithrombotic), and bezafibrate (antilipemic) in wastewater influent are
close to the measured ones, and the ratios of PEC/MEC were 1.22, 1.35,
0.80, and 1.87, respectively. These pharmaceuticals are drugs for
treating specific diseases, and they are strictly controlled by govern-
ment agencies, implying that their consumption is strongly related to
their reported sales. In addition, their stability in sewage (i.e., poor
biodegradability of carbamazepine and its metabolites) can reduce the
influence of sewers on concentration prediction. Thus, the consumption
pattern and excretion efficiencies adopted in the calculation could be
considered acceptable for their prediction in wastewater influent.
3.2. Prioritization of pharmaceuticals in wastewater influent
Chemical analysis of exogenous biomarkers of drug consumption in
wastewater has been shown to have promise for studying drug use
within a defined population (Thomas and Reid, 2011). For example,
Ong et al. demonstrated through the use of target pharmaceuticals in
wastewater plants that the major groups in Australia are heart medi-
cations and statins (lipid-lowering agents) (Ong et al., 2018). Con-
sidering the environmental risk of priority pharmaceuticals, an ap-
proximation using a calculation method would be very helpful. Hence,
the PECs were estimated of pharmaceuticals listed in the Japanese
Annual Report on Pharmaceutical Industries (Ministry of Health,
Labour and Welfare, Japan, 2018), and a reverse analysis developed of
wastewater based on epidemiology (using the prediction model de-
scribed previously). As shown in Fig. 2, for pharmaceutical yearly sales,
antiallergic, analgesic, digestive, and antibiotic pharmaceuticals were
dominant. Although excretion efficiencies vary with different pharma-
ceuticals, analgesics and psychotropics have low excretion efficiencies,
indicating their possible lower priority in wastewater influent despite
their higher sales data.
As shown in Table S2, pranlukast and carbocysteine are pharma-
ceuticals consumed in the greatest quantities, with 4080.3 t and
1372.6 t consumed per year, respectively. These high consumption le-
vels could be attributed to the fact that Japan was the first country in
the world to introduce pranlukast to the market for the treatment of
bronchial asthma (Suissa and Ernst, 2003), and that the Japanese
market has promoted use of carbocysteine as a well-known mucoactive
and mucoregulatory drug (Ishiura et al., 2003). Moreover, the pre-
valence of asthma in Japan has been reportedly increasing (Fukutomi
et al., 2011). The significant consumption of antagonist, mucolytic, and
hypoglycemic pharmaceuticals is due to the aging population in Japan.
Carballa et al. reported that the pharmaceutical consumed in the
highest amount in Spain was ibuprofen (276.1 tons), and compared
annual per capita consumption of 17 pharmaceuticals in different
countries (Carballa et al., 2008). Ottmar et al. demonstrated that the
top prescription rankings in the United States included lisinopril,
atorvastatin, and amoxicillin (Ottmar et al., 2010). As expected, the
consumption of active compounds varies strongly from country to
country.
Although sales data on certain pharmaceuticals apparently indicate
significant consumption levels, their discharge load rankings can be
lower than their sales data rankings because of low excretion effi-
ciencies. For example, PECinf of pranlukast was 257.0 μg/L with ex-
cretion efficiency of 86.6% (Down et al., 1974; Nakashima et al., 1993),
indicating that pranlukast is the most prevalent pharmaceutical in
wastewater influent. Although the yearly sale of rebamipide was
363.0 t, which is higher than that of iopamidol (309.9 t), the excretion
efficiencies of rebamipide and iopamidol were 10% (Naito and
Yoshikawa, 2010) and 100% (Pharmaceuticals and Medical Devices
Agency, Japan), respectively, meaning that the PECinf of rebamipide
(2.6 μg/L) was considerably lower than that of iopamidol (22.5 μg/L).
Based on their excretion efficiencies, the PECs of pranlukast, ethyl
icosapentate, carbocysteine, metformin, iopamidol, salicylic acid, acy-
clovir, iohexol, levofloxacin, and povidone iodine would be expected to
have extremely high values in wastewater influent (> 10 μg/L), and 36
pharmaceuticals would be expected to have high concentrations in
wastewater influent (> 1 μg/L). Among these pharmaceuticals with
high concentrations, analgesics/anti-inflammatories and antibiotics
appear to be the predominant groups in wastewater influent. Further-
more, some specific pharmaceuticals, such as allopurinol, were pre-
dicted for the first time in Japan (1.8 μg/L). Although the PEC of
metformin in wastewater influent was predicted to be 24.1 μg/L, no
study has yet evaluated its concentration in Japanese wastewater. In
other studies, metformin was widely detected at a frequency of occur-
rence of 100% and an average concentration of 8.1 μg/L (Burns et al.,
2018); the order of magnitude of its PEC in Japanese wastewater was
similar to those reported in other countries (Oosterhuis et al., 2013;
Tisler and Zwiener, 2018; Yan et al., 2019). Even though a wide variety
of pharmaceuticals can be found in wastewater influent, it should be
noted that not all their concentrations can be determined. Thus, the
present study has provided a list of pharmaceuticals that warrant fur-
ther investigation due to their high PEC values.
3.3. Evaluation of PEC in wastewater effluent
Table S3 in Supplementary material and Fig. 3 show that removal
efficiencies of pharmaceuticals in Japanese WWTPs predicted by the
EPI suite are within the range of, or less than observed removal effi-
ciencies, allowing for considerable scatter in the results. According to
the criteria in Table 1, the accurate level could be 0.5 < ratio < 2″,
and 19 compounds could be fit for the criteria in Fig. 3. The EPI suite
adequately simulated the removal of biodegradable pharmaceuticals
such as acetaminophen, naproxen, and ibuprofen (the ratios of their
predicted removal efficiencies and observed removal efficiencies were
0.77, 1.91, and 1.16, respectively), which have high biodegradability
and relatively weak sorption in WWTPs, as shown in previous studies
(He et al., 2018; Min et al., 2018; Onesios et al., 2009; Tiwari et al.,
2017). Estimated removals using the EPI suite were calculated from the
biodegradability related to chemical structure and Koc coefficients for
sorption. From the perspective of chemical characteristics, the EPI suite
performed better in estimating the removals of analgesics and hypoli-
pidemic agents, such as acetaminophen, bezafibrate, naproxen, gemfi-
brozil, and ibuprofen (75.1%, 60.6%, 95.3%, 97.2%, and 94.9%, re-
spectively).
Differences between reported and EPI estimated removal effi-
ciencies were observed for antibiotics such as ciprofloxacin and clari-
thromycin; these antibiotics have poor biodegradability, but it has been
previously found that they can be adsorbed in activated sludge (Min
et al., 2018; Tiwari et al., 2017). In practice, it is difficult to predict
accurately the sorption of pharmaceuticals in sludge, owing to factors
such as pH in WWTPs (Ternes et al., 2004).
Discrepancies in removal efficiencies were observed by Verlicchi
et al. (2012) who found that removal efficiencies in WWTPs were
correlated to their characteristics, including biological reactor shape,
operating conditions (solids retention time (SRT), hydraulic retention
time (HRT), pH, redox conditions, etc.) and the water quality of the
influent. Onesios et al. reported that removal of clarithromycin ranged
from 0 to 54%, whereas the range of ofloxacin removal was from 23.8%
to 94.0% (Onesios et al., 2009). Thus, in wastewater effluent, PEC
calculations based on generalized data may be vulnerable to a high
degree of inaccuracy because of different operating condition or was-
tewater composition (Choi et al., 2020). To compensate for these dis-
crepancies, Coetsier et al. suggested adopting either the mean of a wide
range of published data if available, or else considering an extreme
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scenario (Coetsier et al., 2009). Although the PEC could be over-
estimated, predicted removal efficiencies should be less than reported
removal efficiencies. Turning to the extreme scenario concept, the re-
sults predicted by the EPI suite appear acceptable, as shown in Fig. 3,
and so the EPI suite was applied herein to predict removal efficiencies.
After applying the predicted removal efficiencies and predicted
concentrations in the influent (36 pharmaceuticals with high con-
centrations, > 1 μg/L as discussed above), the concentration of these
pharmaceuticals in the effluent was predicted (Table S2 in
Supplementary material), and Table S2 provides the full information of
PECs in the influent and effluent of WWTPs. Among the selected
pharmaceuticals, 26 pharmaceuticals were considered important in the
effluent due to their high concentrations (> 1 μg/L), including 6
pharmaceuticals with concentrations in excess of 10 μg/L. Of these
pharmaceuticals, the PEC of pranlukast in wastewater effluent was the
most significant (203.8 μg/L) because of its low predicted removal ef-
ficiency by the EPI suite. Although the concentrations of several phar-
maceuticals such as iopamidol and levofloxacin have been reported to
be high in wastewater or receiving water in Japan (Azuma et al., 2018;
Watanabe et al., 2016), the occurrence of other pharmaceuticals with
high concentrations (i.e., povidone iodine, carbocysteine, and cefa-
zolin) have not been reported in Japan previously, and these results
provide a concerning list of pharmaceuticals that pose an environ-
mental risk to aquatic environments. For those pharmaceuticals (> 1
μg/L) not measured in Japan, such as allopurinol, its PECinf and PECeff
in this study were 1750.10, and 436.47 ng/L, respectively. In other
countries, the PECinf of allopurinol was reported to be 1000 ng/L
(Sedlak and Pinkston, 2011) and 4360 ng/L (Lacorte et al., 2018); and
Fig. 2. Yearly sale loads and PECs in wastewater influent of pharmaceuticals by their classification (a), and the excretion efficiencies referring to the classification of
pharmaceuticals (b).
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the MECinf was reported as 600 ng/L (Grünebaum, 2011) and 3000 ng/
L (Khan and Ongerth, 2004), as well as that its MECeff was 2000 ng/L
(Khan and Ongerth, 2004) and 1700 ng/L (Gómez-Canela et al., 2019).
Based on above values, similar concentration behavior of allopurinol
was found in Japan and other countries. Furthermore, for famotidine,
its PECinf and PECeff in this study were 1268.22, and 989.47 ng/L, re-
spectively; its MECinf was reported to be 10–210 ng/L (Ahmed et al.,
2017) and 273 ± 164 ng/L (Campos-Mañas et al., 2017); its MECeff
was 132 ng/L with 84.0% of removal efficiency in membrane reactor
(Dolar et al., 2012), and famotidine showed different influent con-
centration level in Japan from other countries. Therefore, the perfor-
mance of pharmaceutical consumption can be evaluated by comparison
of PEC or MEC in Japan and other countries.
At present, the EPI suite does not take into account the transfor-
mation and removal of pharmaceutical metabolites. From a risk as-
sessment perspective, metabolites may be responsible for as much ob-
served environmental toxicity as their parent compounds (Escher and
Fenner, 2011). The EPI suite includes biodegradation and sorption in
activated sludge but does not consider advanced treatment processes,
such as ozonation, advanced oxidation process (AOP), and chlorination,
which could lead to lower effluent concentrations.
3.4. Implication for environmental risk assessment
Environmental risk prioritization is important because it identifies
the highest risk pharmaceuticals that warrant further investigation and
monitoring (Guo et al., 2016). Evaluation of the PEC of pharmaceuticals
and their PNEC calculated from the ECOSAR and KATE system showed
that the PEC-to-PNEC ratios for 19 pharmaceuticals were above 0.1
(Table S2 in Supplementary material), indicating high toxicity in the
aquatic environment, and 54 pharmaceuticals had ratios exceeding
0.01, indicating their toxicities should be evaluated in detail, including
19 pharmaceuticals with median toxicities (PEC-to-PNEC ratios above
0.1). It is worth noting that the environmental risks of several phar-
maceuticals such as bezafibrate (0.074) and sulfamethoxazole (0.021)
have been evaluated in previous Japanese studies (Komori et al., 2013),
but the environmental risks of other pharmaceuticals, including toco-
pherol salt, teprenone, and azelnidipine, which were observed at high
concentrations in Japanese wastewater effluent, have not previously
been reported. The present study has provided a list of pharmaceuticals
for which a comprehensive risk estimate is required. Fig. 4 classifies
pharmaceuticals into four groups according to toxicity and concentra-
tion: (I) attention-worthy toxicity and attention-worthy concentration;
(II) attention-worthy toxicity and negligible concentration; (III) negli-
gible toxicity and negligible concentration; and (IV) negligible toxicity
and attention-worthy concentration. From the perspective of safety, the
risks posed by pharmaceuticals in groups I, II, and IV need to be eval-
uated in the future. For pharmaceuticals in categories (I) and (II), in
order to alleviate the environmental risk, advanced treatments are
suggested for their effective removals, including ozonation for triclosan
(Orhon et al., 2017), and ozonated microbubbles for bicalutamide
(Azuma et al., 2019a,b).
In summary, the present sale-based prediction method has provided
acceptable estimates of influent pharmaceutical concentrations. The
resulting predictions indicate the extent to which previous environ-
mental analyses have ignored several of the most potentially proble-
matic pharmaceuticals, such as pranlukast and carbocysteine. The STP
script in the EPI suite proved useful in evaluating the significant dis-
charge of pharmaceuticals from WWTPs, and in highlighting important
pharmaceuticals in an extreme scenario. In particular, the occurrence of
several pharmaceuticals, such as metformin, is noteworthy and requires
further investigation, because these drugs exhibit high effluent con-
centration levels and pose significant potential environmental risks.
Besides providing the prediction of pharmaceuticals in wastewater
system with their environmental risks, the limitations of this study were
presented. First, Besides the difference between local consumption and
national consumption of pharmaceuticals, unknown sources of phar-
maceuticals discharge were unable to be applied in this study. Second,
wastewater composition may affect the transformation of pharmaceu-
ticals, which was not investigated due to the lack of data in the lit-
erature (Choi et al., 2020). Third, for pharmaceuticals, the transfor-
mation of metabolites was not considered in this study, for example, de-
glucuronidation of phase-II metabolites can result in higher con-
centrations of the parent compound, with higher measured environ-
mental concentrations (Gauderat et al., 2016; Gao et al., 2018; He et al.,
2019).
4. Conclusions
The present study has demonstrated that sales data of pharmaceu-
ticals in Japan can be used for the prediction of pharmaceuticals in
wastewater influent. The main findings are summarized as follows:
(1) According to reverse analysis of epidemiology for wastewater pre-
diction, the PECs of 36 pharmaceuticals had high values in waste-
water influent and so need further, detailed investigation.
Pranlukast had the highest PEC in wastewater influent in Japan
(257.0 μg/L).
(2) By applying the EPI suite to the prediction of pharmaceutical re-
movals from wastewater systems and considering the most extreme
Fig. 3. Comparison between predicted (EPI suite) and measured (from open
literature) removal efficiencies.
Fig. 4. PEC and environmental risk (ratio of PEC and PNEC) in wastewater
effluent caused by the presence of pharmaceuticals.
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scenario, it was predicted that pranlukast was of greatest concern in
wastewater effluent in Japan because of its resistance to biode-
gradation and its high consumption in the Japanese market.
Moreover, 9 pharmaceuticals in the effluent exhibited potentially
high toxicity according to the PEC/PNEC ratio, and 54 pharma-
ceuticals exhibited some toxicity. Therefore, further study is needed
to explore the toxicity of these.
Overall, these findings provide confidence in the use of PECs in
prioritization exercises for pharmaceuticals. Furthermore, the results
prove that reverse analysis of epidemiology can be used widely in the
future to predict environmental risk posed by pharmaceutical dis-
charges. Beyond Japan, the proposed method could be applied to
prioritization of pharmaceutical monitoring activities and environ-
mental risk predictions in other countries.
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